JY
FHTX icon

Jeff Yass’s Foghorn Therapeutics FHTX Stock Holding History

Jeff Yass’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,637
Closed -$55.6K – 13722
2026
Q1 		$55.6K Buy
+11,637
New +$63.9K ﹤0.01% 12608
2025
Q3 		– Sell
-39,649
Closed -$186K – 12822
2025
Q2 		$186K Buy
39,649
+7,799
+24% +$32.6K ﹤0.01% 11282
2025
Q1 		$116K Buy
31,850
+16,052
+102% +$73.2K ﹤0.01% 11439
2024
Q4 		$74.6K Sell
15,798
-23,793
-60% -$173K ﹤0.01% 11506
2024
Q3 		$369K Buy
+39,591
New +$287K ﹤0.01% 9159
2024
Q2 		– Sell
-16,080
Closed -$108K – 12368
2024
Q1 		$108K Buy
16,080
+4,749
+42% +$26.4K ﹤0.01% 11172
2023
Q4 		$73.1K Sell
11,331
-20,007
-64% -$86.3K ﹤0.01% 11525
2023
Q3 		$157K Sell
31,338
-23,684
-43% -$183K ﹤0.01% 10504
2023
Q2 		$387K Buy
55,022
+42,365
+335% +$296K ﹤0.01% 8906
2023
Q1 		$78.5K Buy
+12,657
New +$82.8K ﹤0.01% 11446
2021
Q1 		– Sell
-27,939
Closed -$566K – 12416
2020
Q4 		$566K Buy
+27,939
New +$535K ﹤0.01% 8008

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Jeff Yass's FHTX Position: Q2 2026 in Review

Jeff Yass sold out of Foghorn Therapeutics (FHTX) in Q2 2026, closing a stake of 11,637 shares — an estimated $55.6K sold.

Jeff Yass first reported a position in FHTX in Q4 2020 and held it in 11 quarters. The position peaked at $566K in Q4 2020. 102 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Jeff Yass reported no remaining Foghorn Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 11,637 Foghorn Therapeutics shares in Q2 2026, an estimated $55.6K.
  • Jeff Yass first reported a position in Foghorn Therapeutics in Q4 2020 and held it in 11 quarters.
  • Jeff Yass's Foghorn Therapeutics position peaked at $566K in Q4 2020.
  • 102 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.